查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1632577

全球转甲状腺素类淀粉沉积症治疗市场：市场规模、份额和趋势分析（按治疗方法、类型、疾病、分销管道、地区和细分，2025-2030 年）

Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

转甲状腺素类淀粉沉积症治疗市场的成长与趋势：

根据 Grand View Research 的新报告，全球转甲状腺素类淀粉沉积症治疗市场预计到 2030 年将达到 165.3 亿美元。

预计 2025 年至 2030 年期间市场复合年增长率为 13.9%。转甲状腺素类淀粉沉积症治疗市场主要受到支持性报销计划和不断增长的非裔美国人口的推动。由于非裔美国更容易患 ATTR类淀粉沉积症，非裔美国人口的增加在整个时期内成为了该行业成长的催化剂。 Val122Ile 是导致全球 65 岁或以上人群患心肌病的最常见突变。此外，全球 3% 至 4% 的非裔美国存在 Val122Ile 突变。

预计，加强开发新诊断技术和多学科治疗方法的研究活动将提高转甲状腺素类淀粉沉积症的存活率和改善预后。例如，2019年11月，类淀粉沉积症研究联盟开发了一种特异性疾病的患者报告结果（PRO）工具，以从患者的观点了解和衡量转甲状腺素类淀粉沉积症的影响。透过了解疾病的复杂性和患者的需求，这些工具的引入将促进对新目标特异性药物的开发研究，从而扩大转甲状腺素类淀粉沉积症治疗市场的机会。

主要企业采取的策略性倡议，例如提高对 ATTR 等目标疾病的认识以及现有治疗方法的长期益处，预计将推动该行业的发展。例如，2019年，辉瑞与世界心臟联盟合作发起了「心臟英雄」宣传活动。透过此次宣传活动，辉瑞公司向患者和医生提供与 ATTR-CM 相关的教育资讯和资源。希望此类宣传活动能促进 ATTR-CM 的早期诊断并提高长期治疗率。

作为企业社会责任 (CSR) 活动的一部分，主要企业提供免费医疗服务的措施也有望推动市场成长。例如，辉瑞的病患援助计画为符合资格的病患免费提供辉瑞药物，包括 VYNDAMAX。被诊断患有类淀粉沉积症的人可以在 Vandalink 平台上註册以享受此类计划。希望该计画能鼓励医生将该药物作为转甲状腺素类淀粉沉积症患者的药物治疗。

转甲状腺素类淀粉沉积症治疗市场：分析概述

  • 依照类型划分，由于疾病盛行率高且老龄人口不断增加，到 2024 年，ATTR-CM 将占据主要份额。预计 ATTR-PN 将在整个预测期内呈现最快的成长率。该领域的成长归功于强大的管道。
  • 根据治疗方法，由于全球范围内对 ATTR-CM 治疗的治疗方法的核准和处方率不断提高，标靶治疗领域将在 2024 年占据主导地位。
  • 根据疾病类型，遗传性转甲状腺素类淀粉沉积症变性类疾病在 2024 年占据了市场主导地位。这是由于药物研发管道不断扩大以及各製药公司之间以药物开发为目标的策略联盟不断扩大。
  • 按分销管道划分，预计医院药房将在 2024 年占据最大份额，因为大多数医院都从事转甲状腺素类淀粉沉积症的诊断、研究和治疗。
  • 2024 年，北美地区占据最大份额，这得益于该地区新药处方的增加、优惠的报销政策以及较高的治疗率。
  • 预计中东和非洲地区在整个预测期内将呈现最快的成长率。此细分市场的成长归因于 ATTR类淀粉沉积症盛行率的增加。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. 转甲状腺素类淀粉沉积症治疗市场：驱动因素、趋势与范围

  • 市场联动展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTEL 分析

第 4 章 转甲状腺素类淀粉沉积症治疗市场：依治疗方法进行的商业分析

  • 治疗方法的市场占有率（2024 年和 2030 年）
  • 治疗方法仪表板
  • 市场规模预测及治疗方法趋势分析（2018-2030）
  • 标靶治疗
  • 支持治疗
  • 管道疗法

第 5 章 转甲状腺素类淀粉沉积症治疗市场：按类型进行的商业分析

  • 按类型分類的市场占有率（2024 年和 2030 年）
  • 按类型分類的仪表板
  • 按类型分類的市场规模预测及趋势分析（2018-2030）
  • ATTR神经病变(ATTR-PN)
  • ATTR心肌病(ATTR-CM)

6. 转甲状腺素类淀粉沉积症治疗市场：依疾病进行的商业分析

  • 各疾病的市场占有率（2024 年和 2030 年）
  • 疾病仪表板
  • 市场规模预测及疾病趋势分析（2018-2030）
  • 遗传性转甲状腺素类淀粉沉积症
  • 野生型类淀粉沉积症

7. 转甲状腺素类淀粉沉积症治疗市场：按分销管道进行的业务分析

  • 按分销管道分類的市场占有率（2024 年和 2030 年）
  • 分销通路仪表板
  • 按分销管道分類的市场规模预测及趋势分析（2018-2030 年）
  • 医院药房
  • 专业药房
  • 零售药局
  • 网路药局

第 8 章 转甲状腺素类淀粉沉积症治疗市场：按地区分類的估计和趋势分析

  • 各地区市场占有率（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 按国家/地区划分（2018-2030 年）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分（2018-2030 年）
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 按国家/地区划分（2018-2030 年）
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分（2018-2030 年）
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 按国家/地区划分（2018-2030 年）
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争格局

  • 参与企业概况
  • 公司市场地位分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Pfizer Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals
    • AstraZeneca
    • Akcea Therapeutics
    • BridgeBio Inc.
    • Intellia Therapeutics, Inc.
    • SOM BIOTECH
    • Oncopeptides AB
    • Takeda Pharmaceutical Company Limited
Product Code: GVR-4-68039-977-9

Transthyretin Amyloidosis Treatment Market Growth & Trends:

The global transthyretin amyloidosis treatment market size is anticipated to reach USD 16.53 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 13.9% from 2025 to 2030. The transthyretin amyloidosis treatment market is mainly driven by the presence of supportive reimbursement programs and the growing African American population. The increasing African American population acted as a catalyst for the industry growth throughout the period owing to the high susceptibility to ATTR amyloidosis. The Val122Ile is the most prevalent mutation worldwide that leads to cardiomyopathy among the population specific to aged 65 years and above. Furthermore, this Val122Ile mutation is present in 3% to 4% of the African American population worldwide.

An increase in research activities for the development of novel diagnostic techniques and multidisciplinary therapeutic approaches is expected to lead to an increased survival rate and a more favorable prognosis of transthyretin amyloidosis. For instance, in November 2019, the Amyloidosis Research Consortium developed a disease-specific patient-reported outcome (PRO) tool to understand and measure the impact of transthyretin amyloidosis from the patient perspective. An introduction of such a tool will boost the research in developing a new target-specific drug by understanding disease complexity and patients' need, thereby widening the opportunity in the transthyretin amyloidosis treatment market.

Strategic initiatives undertaken by major players such as creating awareness regarding the target conditions such as ATTR and the long-term benefits of available therapies are expected to fuel industry growth. For instance, in 2019, Pfizer, Inc., in collaboration with the World Heart Federation, started the "Heart Hero" campaign. Under this campaign, Pfizer, Inc. provides educational information and resources related to ATTR-CM to patients and physicians. Such campaigns are expected to boost the early diagnosis of the disease and increase the treatment rate over time.

The movement undertaken by key players to provide free-of-cost medicine under their CSR activities is also projected to fuel market growth. For instance, the Pfizer Patient Assistance Program provides Pfizer medicines such as VYNDAMAX free of cost to eligible patients. People diagnosed with amyloidosis can take advantage of such programs by enrolling at the Vandalink platform. Such programs are expected to encourage physicians to prescribe this drug to a patient as drug therapy in transthyretin amyloidosis patients.

Transthyretin Amyloidosis Treatment Market Report Highlights:

  • By type, the ATTR-CM accounted for a leading share in 2024 owing to the high prevalence of the disease and the rising geriatric population. The ATTR-PN is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the presence of a strong pipeline
  • By therapy, the targeted therapy segment grabbed a dominant share in 2024 owing to the worldwide approval of the therapies and the growing prescription rate for the treatment of ATTR-CM
  • By disease type, the hereditary transthyretin amyloidosis segment dominated the market in 2024 owing to growing strategic alliances among various pharmaceutical companies aiming toward drug development along with growing pipeline drugs
  • By distribution channel, the hospital pharmacies captured the largest share in 2024 as most of the hospitals are working toward the diagnosis, research, and treatment of transthyretin amyloidosis
  • North America region held the largest share in 2024 owing to the increasing novel drug prescription, proper reimbursement policies, and higher treatment rates in the region
  • The MEA region is expected to exhibit the fastest growth rate throughout the forecast period. The segment growth is attributed to the increasing incidence of ATTR amyloidosis

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Type
    • 1.2.3. Disease
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Transthyretin Amyloidosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Transthyretin Amyloidosis Treatment Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2024 & 2030
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
    • 4.4.2. Vyndaqel/ Vyndamax
      • 4.4.2.1. Vyndaqel/ Vyndamax Market, 2018 - 2030 (USD Million)
    • 4.4.3. Onpattro
      • 4.4.3.1. Onpattro Market, 2018 - 2030 (USD Million)
    • 4.4.4. Amvuttra
      • 4.4.4.1. Amvuttra Market, 2018 - 2030 (USD Million)
    • 4.4.5. Tegsedi
      • 4.4.5.1. Tegsedi Market, 2018 - 2030 (USD Million)
    • 4.4.6. Wainua
      • 4.4.6.1. Wainua Market, 2018 - 2030 (USD Million)
  • 4.5. Supportive Therapy
    • 4.5.1. Supportive Therapy Market, 2018 - 2030 (USD Million)
  • 4.6. Pipeline Therapy
    • 4.6.1. Pipeline Therapy Market, 2018 - 2030 (USD Million)

Chapter 5. Transthyretin Amyloidosis Treatment Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. ATTR with Polyneuropathy (ATTR-PN)
    • 5.4.1. ATTR with Polyneuropathy (ATTR-PN) Market, 2018 - 2030 (USD Million)
  • 5.5. ATTR with Cardiomyopathy (ATTR-CM)
    • 5.5.1. ATTR with Cardiomyopathy (ATTR-CM) Market, 2018 - 2030 (USD Million)

Chapter 6. Transthyretin Amyloidosis Treatment Market: Disease Business Analysis

  • 6.1. Disease Market Share, 2024 & 2030
  • 6.2. Disease Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 6.4. Hereditary Transthyretin Amyloidosis
    • 6.4.1. Hereditary Transthyretin Amyloidosis Market, 2018 - 2030 (USD Million)
    • 6.4.2. Polyneuropathy
      • 6.4.2.1. Polyneuropathy Market, 2018 - 2030 (USD Million)
    • 6.4.3. Cardiomyopathy
      • 6.4.3.1. Cardiomyopathy Market, 2018 - 2030 (USD Million)
    • 6.4.4. Mixed Type
      • 6.4.4.1. Mixed Type Market, 2018 - 2030 (USD Million)
  • 6.5. Wild Type Amyloidosis
    • 6.5.1. Wild Type Amyloidosis Market, 2018 - 2030 (USD Million)

Chapter 7. Transthyretin Amyloidosis Treatment Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Specialty Pharmacies
    • 7.5.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Retail Pharmacies
    • 7.6.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.7. Online Pharmacies
    • 7.7.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Transthyretin Amyloidosis Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Transthyretin Amyloidosis Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Alnylam Pharmaceuticals, Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Ionis Pharmaceuticals
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. AstraZeneca
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Akcea Therapeutics
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. BridgeBio Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Intellia Therapeutics, Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. SOM BIOTECH
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Oncopeptides AB
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Takeda Pharmaceutical Company Limited
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global transthyretin amyloidosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 5 Global transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 6 Global transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 7 Global transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 North America transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 10 North America transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 11 North America transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 12 North America transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 U.S. transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 15 U.S. transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 16 U.S. transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Canada transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 18 Canada transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 19 Canada transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 20 Canada transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 22 Mexico transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 23 Mexico transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 24 Mexico transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Europe transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 27 Europe transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 28 Europe transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 29 Europe transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 UK transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 31 UK transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 32 UK transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 33 UK transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Germany transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 35 Germany transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 36 Germany transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 37 Germany transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 France transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 39 France transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 40 France transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 41 France transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Italy transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 43 Italy transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 44 Italy transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 45 Italy transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 Spain transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 47 Spain transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 48 Spain transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 49 Spain transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Denmark transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 51 Denmark transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 52 Denmark transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 53 Denmark transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Sweden transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 55 Sweden transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 56 Sweden transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 57 Sweden transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Norway transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 59 Norway transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 60 Norway transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 61 Norway transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 China transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 68 China transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 69 China transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 70 China transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Japan transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 72 Japan transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 73 Japan transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 74 Japan transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 India transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 76 India transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 77 India transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 78 India transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Australia transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 80 Australia transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 81 Australia transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 82 Australia transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 84 South Korea transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 85 South Korea transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 86 South Korea transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Thailand transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 88 Thailand transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 89 Thailand transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 90 Thailand transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 92 Latin America transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 93 Latin America transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 94 Latin America transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 95 Latin America transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96 Brazil transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 97 Brazil transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 98 Brazil transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 99 Brazil transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100 Argentina transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 101 Argentina transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 102 Argentina transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 103 Argentina transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Transthyretin amyloidosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109 South Africa transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 110 South Africa transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 111 South Africa transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 112 South Africa transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117 UAE transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 118 UAE transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 119 UAE transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 120 UAE transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121 Kuwait transthyretin amyloidosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 122 Kuwait transthyretin amyloidosis treatment market, by type, 2018 - 2030 (USD Million)
  • Table 123 Kuwait transthyretin amyloidosis treatment market, by disease, 2018 - 2030 (USD Million)
  • Table 124 Kuwait transthyretin amyloidosis treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Transthyretin amyloidosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapy and type outlook (USD Million)
  • Fig. 10 Disease and distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Transthyretin amyloidosis treatment market dynamics
  • Fig. 13 Transthyretin amyloidosis treatment market: Porter's five forces analysis
  • Fig. 14 Transthyretin amyloidosis treatment market: PESTLE analysis
  • Fig. 15 Transthyretin amyloidosis treatment market: Therapy segment dashboard
  • Fig. 16 Transthyretin amyloidosis treatment market: Therapy market share analysis, 2024 & 2030
  • Fig. 17 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Vyndaqel/ Vyndamax market, 2018 - 2030 (USD Million)
  • Fig. 19 Onpattro market, 2018 - 2030 (USD Million)
  • Fig. 20 Amvuttra market, 2018 - 2030 (USD Million)
  • Fig. 21 Tegsedi market, 2018 - 2030 (USD Million)
  • Fig. 22 Wainua market, 2018 - 2030 (USD Million)
  • Fig. 23 Supportive therapy market, 2018 - 2030 (USD Million)
  • Fig. 24 Pipeline Therapy market, 2018 - 2030 (USD Million)
  • Fig. 25 Transthyretin amyloidosis treatment market: Type segment dashboard
  • Fig. 26 Transthyretin amyloidosis treatment market: Type market share analysis, 2024 & 2030
  • Fig. 27 ATTR with Polyneuropathy (ATTR-PN) market, 2018 - 2030 (USD Million)
  • Fig. 28 ATTR with Cardiomyopathy (ATTR-CM) market, 2018 - 2030 (USD Million)
  • Fig. 29 Transthyretin amyloidosis treatment market: Disease segment dashboard
  • Fig. 30 Transthyretin amyloidosis treatment market: Disease market share analysis, 2024 & 2030
  • Fig. 31 Hereditary transthyretin amyloidosis market, 2018 - 2030 (USD Million)
  • Fig. 32 Polyneuropathy market, 2018 - 2030 (USD Million)
  • Fig. 33 Cardiomyopathy market, 2018 - 2030 (USD Million)
  • Fig. 34 Mixed type market, 2018 - 2030 (USD Million)
  • Fig. 35 Wild type amyloidosis market, 2018 - 2030 (USD Million)
  • Fig. 36 Transthyretin amyloidosis treatment market: Distribution channel segment dashboard
  • Fig. 37 Transthyretin amyloidosis treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 38 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 39 Specialty pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 40 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 41 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 42 Transthyretin amyloidosis treatment market revenue, by region
  • Fig. 43 Regional marketplace: Key takeaways
  • Fig. 44 Regional marketplace: Key takeaways
  • Fig. 45 North America transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. country dynamics
  • Fig. 47 U.S. transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Canada country dynamics
  • Fig. 49 Canada transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Mexico country dynamics
  • Fig. 51 Mexico transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Europe transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 UK country dynamics
  • Fig. 54 UK transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 Germany country dynamics
  • Fig. 56 Germany transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 France country dynamics
  • Fig. 58 France transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Italy country dynamics
  • Fig. 60 Italy transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 Spain country dynamics
  • Fig. 62 Spain transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Norway country dynamics
  • Fig. 64 Norway transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Sweden country dynamics
  • Fig. 66 Sweden transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Denmark country dynamics
  • Fig. 68 Denmark transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 Asia Pacific transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 Japan country dynamics
  • Fig. 71 Japan transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 China country dynamics
  • Fig. 73 China transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 India country dynamics
  • Fig. 75 India transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Australia country dynamics
  • Fig. 77 Australia transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 South Korea country dynamics
  • Fig. 79 South Korea transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 80 Thailand country dynamics
  • Fig. 81 Thailand transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 82 Latin America transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 83 Brazil country dynamics
  • Fig. 84 Brazil transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina country dynamics
  • Fig. 86 Argentina transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 87 MEA transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 88 South Africa country dynamics
  • Fig. 89 South Africa transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 90 Saudi Arabia country dynamics
  • Fig. 91 Saudi Arabia transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 92 UAE country dynamics
  • Fig. 93 UAE transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 94 Kuwait country dynamics
  • Fig. 95 Kuwait transthyretin amyloidosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 96 Company categorization
  • Fig. 97 Company market position analysis
  • Fig. 98 Strategic framework